Inhibition of respiratory syncytial virus in vitro and in vivo by the immunosuppressive agent leflunomide

Antiviral Therapy

Volumn 16, Issue 3, 2011, Pages 309-317

  Dunn, Melinda C Cox ^a   Knight, Deborah A ^a   Waldman, W James ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; LEFLUNOMIDE; RIBAVIRIN; URIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; EPITHELIUM CELL; FEMALE; HEP 2 CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG HOMOGENATE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RESPIRATORY EPITHELIUM; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SYNCYTIUM; VIRUS CULTURE; VIRUS INHIBITION; VIRUS LOAD;

ANIMALS; ANTIVIRAL AGENTS; BRONCHI; CELL LINE, TUMOR; CYTOPATHOGENIC EFFECT, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; SIGMODONTINAE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 79959444720     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1763     Document Type: Article

References (42)

1. Meissner HC. Selected populations at increased risk from respiratory syncytial virus infection. Pediatr Infect Dis J 2003; 22 Suppl 2:S40-S45. (Pubitemid 36228151)
2. Medrano C, Garcia-Guereta L, Grueso J, et al. Respiratory infection in congenital cardiac disease. Hospitalizations in young children in Spain during 2004 and 2005: the CIVIC Epidemiologic Study. Cardiol Young 2007; 17:360-371.
3. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005; 352:1749-1759. (Pubitemid 40570923)
4. Nair HD, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375:1545-1555.
5. Fleming DM, Elliot AJ. Respiratory syncytial virus: a sleeping giant? Eur Respir J 2007; 30:1029-1031.
6. Kim HW, Kim HW, Canchola JG, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89:422-434.
7. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969; 89:405-421.
8. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization. Pediatrics 1998; 102:531-537.
9. Valeant Pharmaceuticals. Virazole: prescribing information. (Updated November 2008. Accessed 14 March 2011.) Available from http://www.valeant.com/ fileRepository/products/PI/Virazole-Inhalation%20Solution%206gm-PI-Apr02.pdf
10. Maggon K, Barik S. New drugs and treatment for respiratory syncytial virus. Rev Med Virol 2004; 14:149-168. (Pubitemid 38649369)
11. McChesney LP, Xiao F, Sankary HN, et al. An evaluation of leflunomide in the canine renal transplantation model. Transplantation 1994; 57:1717-1722. (Pubitemid 24206409)
12. Williams JW, Xiao F, Foster P, et al. Leflunomide in experimental transplantation. Control of rejection and alloantibody production, reversal of acute rejection, and interaction with cyclosporine. Transplantation 1994; 57:1223-1231.
13. Xiao F, Chong A, Shen J, et al. Pharmacologically induced regression of chronic transplant rejection. Transplantation 1995; 60:1065-1072.
14. Williams JW, Mital D, Chong A, et al. Experiences with leflunomide in solid organ transplantation. Transplantation 2002; 73:358-366. (Pubitemid 34174284)
15. Silverman E, Mouy R, Spiegel L, et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med 2005; 352:1655-1666. (Pubitemid 40530232)
16. Elder RT, Xu X, Williams JW, Gong H, Finnegan A, Chong AS. The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms. J Immunol 1997; 159:22-27.
17. Waldman WJ, Knight DA, Lurain NS, et al. Novel mechanism of inhibition of CMV by the experimental immunosuppressive agent leflunomide. Transplantation 1999; 68:814-825. (Pubitemid 29468200)
18. Knight DA, Hejmanowski AQ, Dierksheide JE, Williams JW, Chong AS, Waldman WJ. Inhibition of herpes simplex virus type 1 by the experimental immunosuppressive agent leflunomide. Transplantation 2001; 71:170-174. (Pubitemid 32105800)
19. Chong AS, Zeng H, Knight DA, et al. Concurrent antiviral and immunosuppressive activities of leflunomide in vivo. Am J Transplant 2006; 6:69-75. (Pubitemid 43382202)
20. John GT, Manivannan J, Chandy S, Peter S, Jacob CK. Leflunomide therapy for cytomegalovirus disease in renal allograft recipients. Transplantation 2004; 77:1460-1461. (Pubitemid 38668445)
21. John GT, Manivannan J, Chandy S, et al. A prospective evaluation of leflunomide therapy for cytomegalovirus disease in renal transplant recipients. Transplant Proc 2005; 37:4303-4305. (Pubitemid 43016014)
22. Avery RK, Bolwell BJ, Yen-Lieberman B, et al. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection. Bone Marrow Transplant 2004; 34:1071-1075. (Pubitemid 40028840)
23. Levi ME, Mandava N, Chan LK, Weinberg A, Olson JL. Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide. Transpl Infect Dis 2006; 8:38-43.
24. Ehlert K, Groll AH, Kuehn J, Vormoor J. Treatment of refractory CMV-infection following hematopoietic stem cell transplantation with the combination of foscarnet and leflunomide. Klin Padiatr 2006; 218:180-184. (Pubitemid 43805941)
25. Teschner S, Gerke P, Geyer M, et al. Leflunomide therapy for polyomavirus-induced allograft nephropathy: efficient BK virus elimination without increased risk of rejection. Transplant Proc 2009; 41:2533-2538.
26. Williams JW, Javaid B, Kadambi PV, et al. Leflunomide for polyomavirus type BK nephropathy. N Engl J Med 2005; 352:1157-1158.
27. Zhao X, Sullender WM. In vivo selection of respiratory syncytial viruses resistant to palivizumab. J Virol 2005; 79:3962-3968.
28. Chong AS, Huang W, Liu W, et al. In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression. Transplantation 1999; 68:100-109.
29. Durbin JE, Durbin RK. Respiratory syncytial virus-induced immunoprotection and immunopathology. Viral Immunol 2004; 17:370-380. (Pubitemid 39244759)
30. Krishnan S, Halonen M, Welliver RC. Innate immune responses in respiratory syncytial virus infections. Viral Immunol 2004; 17:220-233. (Pubitemid 38880423)
31. Yasui K, Baba A, Iwasaki Y, et al. Neutrophil-mediated inflammation in respiratory syncytial viral bronchiolitis. Pediatr Int 2005; 47:190-195. (Pubitemid 40545424)
32. Bataki EL, Evans GS, Everard ML. Respiratory syncytial virus and neutrophil activation. Clin Exp Immunol 2005; 140:470-477. (Pubitemid 40813957)
33. DeVincenzo JP, El Saleeby CM, Bush AJ. Respiratory syncytial virus load predicts disease severity in previously healthy infants. J Infect Dis 2005; 191:1861-1868. (Pubitemid 40705393)
34. Welliver TP, Garofalo RP, Hosakote Y, et al. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus Is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis 2007; 195:1126-1136. (Pubitemid 46543443)
35. Bennett BL, Garofalo RP, Cron SG, et al. Immunopathogenesis of respiratory syncytial virus bronchiolitis. J Infect Dis 2007; 195:1532-1540. (Pubitemid 46717472)
36. Lin Y, Vandeputte M, Waer M. Suppression of T-independent IgM xenoantibody formation by leflunomide during xenografting of hamster hearts in rats. Transplantation 1998; 65:332-339. (Pubitemid 28095959)
37. Kraan MC, de Koster BM, Elferink JG, Post WJ, Breedveld FC, Tak PP. Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients. Arthritis Rheum 2000; 43:1488-1495. (Pubitemid 30452466)
38. Josephson MA, Gillen D, Javaid B, et al. Treatment of renal allograft polyoma BK virus infection with leflunomide. Transplantation 2006; 81:704-710.
39. Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 1999; 353:259-266. (Pubitemid 29088117)
40. Silverman E, Spiegel L, Hawkins D, et al. Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2005; 52:554-562. (Pubitemid 40216320)
41. Fukushima R, Kanamori S, Hirashiba M, et al. Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice. Reprod Toxicol 2007; 24:310-316. (Pubitemid 350016756)
42. Sidwell RW, Barnard DL. Respiratory syncytial virus infections: recent prospects for control. Antiviral Res 2006; 71:379-390. (Pubitemid 44223774)